Original Article

You have full text access to this OnlineOpen article

Development of Herceptin resistance in breast cancer cells

  1. Timothy Kute1,*,
  2. Christopher M. Lack1,
  3. Mark Willingham1,
  4. Bimjhana Bishwokama2,
  5. Holly Williams1,
  6. Kathy Barrett1,
  7. Tanita Mitchell1,
  8. James P. Vaughn2

Article first published online: 29 DEC 2003

DOI: 10.1002/cyto.a.10095

Issue

Cytometry Part A

Cytometry Part A

Volume 57A, Issue 2, pages 86–93, February 2004

Additional Information

How to Cite

Kute, T., Lack, C. M., Willingham, M., Bishwokama, B., Williams, H., Barrett, K., Mitchell, T. and Vaughn, J. P. (2004), Development of Herceptin resistance in breast cancer cells. Cytometry, 57A: 86–93. doi: 10.1002/cyto.a.10095

Author Information

  1. 1

    Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

  2. 2

    Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

*Department of Pathology, Medical Center Blvd., Winston-Salem, NC 27157-1072

Publication History

  1. Issue published online: 22 JAN 2004
  2. Article first published online: 29 DEC 2003
  3. Manuscript Accepted: 13 AUG 2003
  4. Manuscript Revised: 9 JUL 2003
  5. Manuscript Received: 19 DEC 2002

Funded by

  • Wake Forest University Cancer Center Push Grant
  • National Cancer Institute. Grant Number: RO1-CA 83953

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (290K)

LITERATURE CITED

  • 1
    Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002; 29: 38–43.
  • 2
    Smith IE. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs 2001; 12(Suppl 4): S3–S10.
  • 3
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 2: 719–726.
  • 4
    Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592–1600.
    Direct Link:
  • 5
    Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285–4289.
  • 6
    Vaughn JP, Willingham MC, Barrett KL, Creacy SD, Kute TE. Herceptin alone induces apoptosis in sensitive breast tumor cells overexpressing HER-2 [Abstract]. In: Proceedings of the 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, 2002. p 300.
  • 7
    Kute TE, Shao ZM, Sugg NK, Long RT, Russell GB, Case LD. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992; 52: 5198–203.
  • 8
    Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62: 4132–4141.
  • 9
    Mayfield S, Vaughn JP, Kute TE. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res Treat 2001; 70: 123–129.
  • 10
    Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165–1172.
  • 11
    Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000; 20: 3210–3223.
  • 12
    Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002; 8: 1076–1078.
  • 13
    Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 2002; 8: 1720–1730.
  • 14
    Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127–137.
  • 15
    Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145–1152.
  • 16
    Dugger DL, Hollingshead PG, Wong D, Romero M, Erickson SL, Schwall RH. Acquisition of Herceptin resistance by HER2 mutation in the HER2 transgenic mouse breast cancer model [Late Breaking Abstract]. In: Proceedings of the 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, 2002. p 51.
  • 17
    Chan CT, Kane SE. In vitro selection and preliminary characterization of Herceptin resistant human breast carcinoma cells [Abstract]. In: Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, 2001. p 930.
  • 18
    Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136–1144.
  • 19
    Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153–1160.
View Full Article (HTML) Get PDF (290K)